Bioinformatics and In Vitro/In Vivo Experiments Identify MAD2L1 as an m6A-Associated Biomarker Promoting Oral...

Oral squamous cell carcinoma (OSCC) is a common malignant tumor of the head and neck, and its therapeutic efficacy critically depends on the identification of reliable biomarkers. This study investigates the interplay between m6A methylation-related biomarkers and OSCC progression biomarkers, aiming to enhance the understanding of pathogenic mechanisms and facilitate personalized treatment strategies.

Based on multi-dimensional bioinformatics analyses-including differential expression, enrichment, prognostic modeling, and immune infiltration analyses-of GEO and TCGA datasets, potential biomarkers that promote malignant progression in OSCC and their association with m6A-related molecules were identified. The effect of MAD2L1 on OSCC in vitro was assessed using CCK-8, RT-qPCR, colony formation, wound healing, and TUNEL assays, while Western blotting was employed to explore the underlying mechanisms by which MAD2L1 influences OSCC progression. Additionally, RT-qPCR was used to examine the impact of MAD2L1 on m6A-related biomarkers. Finally, a xenograft tumor model was utilized to evaluate the effect of MAD2L1 on tumor growth in vivo.

Our findings demonstrate that MAD2L1 serves as a biomarker associated with the progression of oral squamous cell carcinoma (OSCC). Specifically, MAD2L1 expression was significantly upregulated in OSCC patients and positively correlated with increasing histopathological grade. Elevated MAD2L1 expression was linked to poor prognosis in OSCC patients and enabled the construction of an effective prognostic model. Furthermore, MAD2L1 expression showed significant positive correlations with multiple m6A-related biomarkers. Knockdown of MAD2L1 reduced the mRNA expression of THDC1, WTAP, and RBMX. In addition, MAD2L1 expression was significantly associated with tumor microenvironment (TME) dysregulation. Finally, both in vitro and in vivo experiments confirmed that MAD2L1 knockdown markedly suppressed OSCC cell growth.

Collectively, our study identifies MAD2L1 as a promising oncogenic biomarker and therapeutic target in OSCC, whose upregulation drives tumor progression, impairs patient prognosis, and disrupts m6A modification.